Given the dual role of ABCG2 and UGT1A1 on efflux and metabolism of the active metabolite of irinotecan, SN-38, we have investigated the potential of SCO-101 to inhibit both ABCG2 and UGT1A1 activity and reverse drug resistance in cancer models. Here, ABCG2 is linked to cancer.